메뉴 건너뛰기




Volumn 9, Issue 9, 2014, Pages 1657-1667

Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

EID: 84908588638     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01600214     Document Type: Article
Times cited : (24)

References (50)
  • 9
    • 0018118982 scopus 로고
    • Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
    • Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299: 1151–1155, 1978.
    • (1978) N Engl J Med , vol.299 , pp. 1151-1155
    • Donadio, J.V.1    Holley, K.E.2    Ferguson, R.H.3    Ilstrup, D.M.4
  • 18
    • 0029788602 scopus 로고    scopus 로고
    • Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus
    • Pryor BD, Bologna SG, Kahl LE: Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39: 1475–1482, 1996.
    • (1996) Arthritis Rheum , vol.39 , pp. 1475-1482
    • Pryor, B.D.1    Bologna, S.G.2    Kahl, L.E.3
  • 19
    • 84869027155 scopus 로고    scopus 로고
    • European Vasculitis Study Group: Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibodyassociated vasculitis
    • Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Höglund P, Jayne DR; European Vasculitis Study Group: Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 64: 3472–3477, 2012.
    • (2012) Arthritis Rheum , vol.64 , pp. 3472-3477
    • Faurschou, M.1    Westman, K.2    Rasmussen, N.3    De Groot, K.4    Flossmann, O.5    Höglund, P.6    Jayne, D.R.7
  • 21
  • 22
    • 84886308944 scopus 로고    scopus 로고
    • Should Pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis?
    • Besada E, Nossent JC: Should Pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis? Clin Rheumatol 32: 1677–1681, 2013.
    • (2013) Clin Rheumatol , vol.32 , pp. 1677-1681
    • Besada, E.1    Nossent, J.C.2
  • 23
    • 0033869056 scopus 로고    scopus 로고
    • Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner’s granulomatosis undergoing immunosuppressive therapy
    • Chung JB, Armstrong K, Schwartz JS, Albert D: Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 43: 1841–1848, 2000.
    • (2000) Arthritis Rheum , vol.43 , pp. 1841-1848
    • Chung, J.B.1    Armstrong, K.2    Schwartz, J.S.3    Albert, D.4
  • 28
    • 79961111815 scopus 로고    scopus 로고
    • Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections
    • Tesfa D, Ajeganova S, Hägglund H, Sander B, Fadeel B, Hafström I, Palmblad J: Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections. Arthritis Rheum 63: 2209–2214, 2011.
    • (2011) Arthritis Rheum , vol.63 , pp. 2209-2214
    • Tesfa, D.1    Ajeganova, S.2    Hägglund, H.3    Sander, B.4    Fadeel, B.5    Hafström, I.6    Palmblad, J.7
  • 29
    • 79959805570 scopus 로고    scopus 로고
    • European Vasculitis Study Group (EUVAS): Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: Follow-up data from European Vasculitis Study Group clinical trials
    • Heijl C, Harper L, Flossmann O, Stücker I, Scott DG, Watts RA, Höglund P, Westman K, Mahr A; European Vasculitis Study Group (EUVAS): Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: Follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 70: 1415–1421, 2011.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1415-1421
    • Heijl, C.1    Harper, L.2    Flossmann, O.3    Stücker, I.4    Scott, D.G.5    Watts, R.A.6    Höglund, P.7    Westman, K.8    Mahr, A.9
  • 30
    • 38149112725 scopus 로고    scopus 로고
    • Malignancies in Wegener’s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients
    • Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B: Malignancies in Wegener’s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100–105, 2008.
    • (2008) J Rheumatol , vol.35 , pp. 100-105
    • Faurschou, M.1    Sorensen, I.J.2    Mellemkjaer, L.3    Loft, A.G.4    Thomsen, B.S.5    Tvede, N.6    Baslund, B.7
  • 31
    • 74849100964 scopus 로고    scopus 로고
    • Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review
    • Monach PA, Arnold LM, Merkel PA: Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis Rheum 62: 9–21, 2010.
    • (2010) Arthritis Rheum , vol.62 , pp. 9-21
    • Monach, P.A.1    Arnold, L.M.2    Merkel, P.A.3
  • 32
    • 0036862103 scopus 로고    scopus 로고
    • Long-term risk of second malignancy after treatment of Hodgkin’s disease: The influence of treatment, age and follow-up time
    • Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaløy S: Long-term risk of second malignancy after treatment of Hodgkin’s disease: The influence of treatment, age and follow-up time. Ann Oncol 13: 1786–1791, 2002.
    • (2002) Ann Oncol , vol.13 , pp. 1786-1791
    • Foss Abrahamsen, A.1    Ersen, A.2    Nome, O.3    Jacobsen, A.B.4    Holte, H.5    Foss Abrahamsen, J.6    Kvaløy, S.7
  • 34
    • 33644821539 scopus 로고    scopus 로고
    • Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil
    • Robson R, Cecka JM, Opelz G, Budde M, Sacks S: Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5: 2954–2960, 2005.
    • (2005) Am J Transplant , vol.5 , pp. 2954-2960
    • Robson, R.1    Cecka, J.M.2    Opelz, G.3    Budde, M.4    Sacks, S.5
  • 35
    • 33749507195 scopus 로고    scopus 로고
    • Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: Analysis of the transplant registry of the International Society for Heart and Lung Transplantation
    • O’Neill JO, Edwards LB, Taylor DO: Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: Analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25: 1186–1191, 2006.
    • (2006) J Heart Lung Transplant , vol.25 , pp. 1186-1191
    • O’Neill, J.O.1    Edwards, L.B.2    Taylor, D.O.3
  • 36
    • 0029759669 scopus 로고    scopus 로고
    • Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study
    • Jones M, Symmons D, Finn J, Wolfe F: Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 35: 738–745, 1996.
    • (1996) Br J Rheumatol , vol.35 , pp. 738-745
    • Jones, M.1    Symmons, D.2    Finn, J.3    Wolfe, F.4
  • 37
    • 40449106365 scopus 로고    scopus 로고
    • Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis
    • Bernatsky S, Clarke AE, Suissa S: Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168: 378–381, 2008.
    • (2008) Arch Intern Med , vol.168 , pp. 378-381
    • Bernatsky, S.1    Clarke, A.E.2    Suissa, S.3
  • 38
    • 0036894860 scopus 로고    scopus 로고
    • Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients
    • Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC: Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29: 2571–2576, 2002.
    • (2002) J Rheumatol , vol.29 , pp. 2571-2576
    • Huong, D.L.1    Amoura, Z.2    Duhaut, P.3    Sbai, A.4    Costedoat, N.5    Wechsler, B.6    Piette, J.C.7
  • 39
    • 4344672490 scopus 로고    scopus 로고
    • Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy
    • Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK: Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 13: 569–574, 2004.
    • (2004) Lupus , vol.13 , pp. 569-574
    • Park, M.C.1    Park, Y.B.2    Jung, S.Y.3    Chung, I.H.4    Choi, K.H.5    Lee, S.K.6
  • 40
    • 84863928729 scopus 로고    scopus 로고
    • Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: Experiences from the Ferti PROTEKT network
    • Henes M, Henes JC, Neunhoeffer E, VonWolff M, Schmalzing M, Kötter I, Lawrenz B: Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: Experiences from the Ferti PROTEKT network. Lupus 21: 953–958, 2012.
    • (2012) Lupus , vol.21 , pp. 953-958
    • Henes, M.1    Henes, J.C.2    Neunhoeffer, E.3    Vonwolff, M.4    Schmalzing, M.5    Kötter, I.6    Lawrenz, B.7
  • 41
    • 54149085155 scopus 로고    scopus 로고
    • Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: A nonrandomized trial and reviewof the literature
    • Cigni A, Faedda R, Atzeni MM, Pileri PV, Alagna S, Rovasio P, Satta AE, Loi MR, Sini A, Satta V, Masala A: Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: A nonrandomized trial and reviewof the literature. Am J Kidney Dis 52: 887–896, 2008.
    • (2008) Am J Kidney Dis , vol.52 , pp. 887-896
    • Cigni, A.1    Faedda, R.2    Atzeni, M.M.3    Pileri, P.V.4    Alagna, S.5    Rovasio, P.6    Satta, A.E.7    Loi, M.R.8    Sini, A.9    Satta, V.10    Masala, A.11
  • 44
    • 0030015937 scopus 로고    scopus 로고
    • Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis
    • Yarboro CH, Wesley R, Amantea MA, Klippel JH, Pucino F: Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis. Ann Pharmacother 30: 752–755, 1996.
    • (1996) Ann Pharmacother , vol.30 , pp. 752-755
    • Yarboro, C.H.1    Wesley, R.2    Amantea, M.A.3    Klippel, J.H.4    Pucino, F.5
  • 45
    • 0030473520 scopus 로고    scopus 로고
    • The Tricontinental Mycophenolate Mofetil Trial
    • Browne BJ: The Tricontinental Mycophenolate Mofetil Trial. Transplantation 62: 1697, 1996.
    • (1996) Transplantation , vol.62 , pp. 1697
    • Browne, B.J.1
  • 46
    • 0029115531 scopus 로고
    • Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil U.S. Renal for the prevention of acute rejection in primary cadaveric renal allograft recipients
    • Sollinger HW; Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil U.S. Renal for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225–232, 1995.
    • (1995) Transplantation , vol.60 , pp. 225-232
    • Sollinger, H.W.1
  • 47
    • 33847000177 scopus 로고    scopus 로고
    • Serum sickness following treatment with rituximab
    • Todd DJ, Helfgott SM: Serum sickness following treatment with rituximab. J Rheumatol 34: 430–433, 2007.
    • (2007) J Rheumatol , vol.34 , pp. 430-433
    • Todd, D.J.1    Helfgott, S.M.2
  • 48
    • 84898813235 scopus 로고    scopus 로고
    • Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review
    • Roubille C, Haraoui B: Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review. Semin Arthritis Rheum 43: 613–626, 2014.
    • (2014) Semin Arthritis Rheum , vol.43 , pp. 613-626
    • Roubille, C.1    Haraoui, B.2
  • 50
    • 0028586015 scopus 로고
    • Structure and alternate tissue-preferred transcription initiation of the mouse alpha B-crystallin/small heat shock protein gene
    • Frederikse PH, Dubin RA, Haynes JI 2nd, Piatigorsky J: Structure and alternate tissue-preferred transcription initiation of the mouse alpha B-crystallin/small heat shock protein gene. Nucleic Acids Res 22: 5686–5694, 1994.
    • (1994) Nucleic Acids Res , vol.22 , pp. 5686-5694
    • Frederikse, P.H.1    Dubin, R.A.2    Haynes, J.I.3    Piatigorsky, J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.